TG Therapeutics keeps rocketing on CLL results

7 March 2017
2019_biotech_test_vial_discovery_big

US development stage company TG Therapeutics (Nasdaq: TGTX) is trading higher again on Tuesday as investors continue to react to Monday’s news that the primary endpoint of its Phase III GENUINE study has been met.

The study was a trial of TG-1101 (ublituximab), a highly potent glycoengineered anti-CD20 monoclonal antibody, in combination with ibrutinib, a drug marketed under the name Imbruvica from US companies AbbVie (NYSE: ABBV) and Johnson & Johnson (NYSE: JNJ), in patients with previously treated high risk chronic lymphocytic leukemia (CLL).

"We believe the regimen has the potential to become the standard of care for patients with high-risk CLL that have progressed from other therapies"

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology